Net Income (Loss) Attributable to Parent in USD of Lomond Therapeutics Holdings, Inc. from Q4 2021 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Lomond Therapeutics Holdings, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q4 2021 to Q3 2025.
  • Lomond Therapeutics Holdings, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$7.96M, a 43.7% decline year-over-year.
  • Lomond Therapeutics Holdings, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$29.8M, a 59.2% decline year-over-year.
  • Lomond Therapeutics Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$17.1M, a 71.9% decline from 2023.
  • Lomond Therapeutics Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$9.94M, a 20243% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Lomond Therapeutics Holdings, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$29.8M -$7.96M -$2.42M -43.7% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$27.4M -$7.33M -$4.22M -136% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$23.1M -$6.2M -$6.05M -3989% 01 Jan 2025 31 Mar 2025 10-Q 20 May 2025
Q4 2024 -$17.1M -$8.29M +$1.62M +16.3% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025
Q3 2024 -$18.7M -$5.54M -$5.53M -50871% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$13.2M -$3.11M -$3.09M -24119% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$10.1M -$152K -$139K -1056% 01 Jan 2024 31 Mar 2024 10-Q 20 May 2025
Q4 2023 -$9.94M -$9.9M -$9.89M -102166% 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025
Q3 2023 -$46.5K -$10.9K +$5.72K +34.5% 01 Jul 2023 30 Sep 2023 10-Q 28 Oct 2024
Q2 2023 -$52.2K -$12.8K +$204 +1.57% 01 Apr 2023 30 Jun 2023 10-Q 28 Oct 2024
Q1 2023 -$52.4K -$13.1K -$3.56K -37.2% 01 Jan 2023 31 Mar 2023 10-Q 28 Oct 2024
Q4 2022 -$48.9K -$9.69K -$3.77K -63.8% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024
Q3 2022 -$45.1K -$16.6K 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 -$13K 01 Apr 2022 30 Jun 2022 10-Q 13 Nov 2023
Q1 2022 -$9.57K 01 Jan 2022 31 Mar 2022 10-Q 13 Nov 2023
Q4 2021 -$5.91K 24 Sep 2021 31 Dec 2021 10-K 31 Mar 2023

Lomond Therapeutics Holdings, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$17.1M -$7.15M -71.9% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025
2023 -$9.94M -$9.89M -20243% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025
2022 -$48.9K 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024
* An asterisk sign (*) next to the value indicates that the value is likely invalid.